COMMUNIQUÉS West-GlobeNewswire

-
BioPorto A/S Announces Changes to the US Commercial Organization
21/10/2024 -
Responsibility statement for first half year of 2024
21/10/2024 -
The Froedtert & MCW Health Network Engages Digital Platform to Roll Out Clinical Nutrition Program to Patients and Employees
21/10/2024 -
PetVivo Engages Another Top Sales Manager, Cindy Gill, for Regional Business Development Manager, as Adoption of Breakthrough Animal MedTech Device Continues to Spread Nationwide
21/10/2024 -
The Ensign Group Announces Appointment of Mark Parkinson to the Board of Directors
21/10/2024 -
Innocan Pharma to Present at the 2024 ThinkEquity Conference
21/10/2024 -
Le KFSHRC ouvre la voie aux diagnostics et aux interventions chirurgicales mini-invasives alimentés par l’IA
21/10/2024 -
PharmAla to supply Mt. Sinai Hospital with LaNeo MDMA
21/10/2024 -
Coloplast A/S - FY 2023/24 Earnings Release - Invitation for conference call on 5 November 2024 at 11.00 CET
21/10/2024 -
Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension
21/10/2024 -
New employee-elected board member
21/10/2024 -
Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219
21/10/2024 -
INVO Bioscience Confirms Corporate Name Change and New Trading Symbol in Connection with Its Recent Merger with NAYA Biosciences
21/10/2024 -
TOMI Environmental Solutions, Inc. Launches SteraMist Integrated System – Standalone (SIS-SA) to Revolutionize Cleanroom and Laboratory Decontamination
21/10/2024 -
Philips showcases next level cardiology innovations for improved patient care at TCT 2024
21/10/2024 -
Novo Nordisk A/S - share repurchase programme
21/10/2024 -
Stereotaxis Technology to be Featured at Annual Meeting of the Society for Cardiac Robotic Navigation
21/10/2024 -
Cerevance Announces Publication of Positive Phase 2 Results of Solengepras for the Treatment of Parkinson’s Disease in eClinicalMedicine
21/10/2024 -
Alpha Tau Announces Acceptance Into FDA’s Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme
21/10/2024
Pages